RWJBarnabas Health Rutgers Cancer Institute of New Jersey
M

Evolution of Treatment Algorithms for HER2+ mBC

By RWJBarnabas Health Rutgers Cancer Institute of New Jersey FEATURING Mridula George
By RWJBarnabas Health Rutgers Cancer Institute of New Jersey FEATURING Mridula George
333 views
September 26, 2024
Comments 0
Login to view comments. Click here to Login

Featured Video

03:15
Lilly Medical Affairs

Unmet Needs and Resistance Mechanisms in Patients With HR+, HER2- MB…

Feat. W. Mchayleh

Featured Video

06:40
Lilly Medical Affairs

Communicating the Risk of Recurrence for Patients With HR+, HER2- Ea…

Feat. J. O’Shaughnessy

Related Videos

25:08

ASCO® 2024 Breast Cancer Highlights - Monday Morning Practice

2024 ASCO® Annual Meeting Insights Hub

S. Tolaney, H. Rugo

4.2K views
12:14

ASCO® 2024 Breast Cancer Highlights: Top 5 Abstracts - DESTINY-Breas…

2024 ASCO® Annual Meeting Insights Hub

P. Tarantino

2.2K views
12:35

SABCS 2023 Summary: "What Is the Appropriate 1L Therapy for ER+ mBC?"

Insights from 2023 SABCS

S. Tolaney, H. Rugo

3.0K views
09:55

ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future Hold?"

2024 ASCO® Annual Meeting Insights Hub

E. Hamilton

1.5K views
05:59
Lilly Medical Affairs

Progression on First-Line Therapy in HR+, HER2- MBC: Treatments and …

Feat. J. O’Shaughnessy
06:39

FDA Approval Clinical Implications: Inavolisib With Palbociclib and …

Memorial Sloan Kettering Cancer Center

K. Jhaveri

617 views
17:12

Strategies for Managing Toxicities of Oral Oncolytics in Breast Canc…

UNC Lineberger Comprehensive Cancer Center

A. Faso, B. Patel, K. Chen

1.5K views
14:16

Year in Review: Breast Cancer

Dana-Farber Cancer Institute

P. Tarantino

2.4K views
14:52

ESMO 2024 Summary: Top 5 Breast Cancer Abstracts - NATALEE, DESTINY-…

2024 ESMO Annual Meeting Insights Hub

P. Tarantino

771 views
08:49

ESMO 2024 Insights: Treatment Rechallenge After Grade 1 Trastuzumab-…

2024 ESMO Annual Meeting Insights Hub

K. Natsuhara

791 views
02:58
Lilly Medical Affairs

A Heterogenous Disease with Varied Clinical Outcomes: HR+/HER2- MBC

Feat. J. O’Shaughnessy
06:14
Lilly Medical Affairs

CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC

Feat. J. O’Shaughnessy
36:18

Metastatic Breast Cancer Comprehensive Review: ESMO Breast 2024 Awar…

Insights from ESMO Breast 2024 Annual Meeting

H. Rugo

1.2K views
03:57
Lilly Medical Affairs

Resistance Mechanisms to ET, Including ESR1 Mutations in HR+, HER2- …

Feat. K. Jhaveri
57:44

Vogl,NY on How to Ask Good Questions at Medical Meetings

Vogl, NY

S. Vogl

5.1K views
17:20

ESMO 2023 Summary: "Top 5 Breast Cancer Studies Including KEYNOTE-75…

Insights from 2023 ESMO Annual Meeting

P. Tarantino

2.1K views
27:01

CDK4/6 Inhibitor Therapy in Early-Stage HR+/HER2- BC

Scripps Health

S. Sammons

1.7K views
33:44

ASCO® 2024 Expert Recap: "Metastatic Breast Cancer Deep Dive & Clini…

2024 ASCO® Annual Meeting Insights Hub

S. Tolaney, H. Rugo

921 views
16:19

Optimizing Adjuvant Treatment in High-Risk HR+/HER2- eBC: Patient Se…

Wassim Mchayleh

884 views
22:34

What's New in Breast Cancer?

Dana-Farber Cancer Institute

S. Tolaney

1.6K views
AUTOPLAY